¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"COM"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
  • JrId: 22927
    JournalTitle: Comparative and functional genomics.
    MedAbbr:
    ISSN: 1531-6912
    ESSN:
    IsoAbbr: Comp. Funct. Genomics
    NlmId: 101090797
  • JrId: 23291
    JournalTitle: Computers and the humanities.
    MedAbbr: Comput Hum
    ISSN: 0010-4817
    ESSN:
    IsoAbbr:
    NlmId: 76274
  • JrId: 23314
    JournalTitle: Communicationes de historia artis medicinae. Suppl.
    MedAbbr: Commun Hist Artis Med Suppl
    ISSN: 0133-946X
    ESSN:
    IsoAbbr:
    NlmId: 8001163
  • JrId: 23900
    JournalTitle: Comparative politics.
    MedAbbr: Comp Polit
    ISSN: 0010-4159
    ESSN:
    IsoAbbr:
    NlmId: 100967244
  • JrId: 23901
    JournalTitle: Comunita.
    MedAbbr: Comunita
    ISSN:
    ESSN:
    IsoAbbr:
    NlmId: 100967246
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • compound lens microscope
    º¹ÇÕ·»ÁîÇö¹Ì°æ
  • compound monster
    ÀϹݺ¹Ã¼±âÇü
  • compound muscle action potential
    º¹ÇÕ±Ù(À°)Ȱµ¿ÀüÀ§
  • compound nerve action potential
    º¹ÇսŰæÈ°µ¿ÀüÀ§
  • compound nevus
    º¹ÇÕ¸ð¹Ý
  • compound presentation
    º¹ÇÕÅÂÀ§
  • compound scan
    º¹ÇÕ½ºÄµ
  • compound sector
    º¹ÇÕºÎä²Ã
  • compounding
    ¹èÇÕ, Á¶Á¦
  • compounding agent
    ¹èÇÕÁ¦, Á¶ÇÕÁ¦
  • comprehension
    ÀÌÇØ
  • comprehensive approach
    Á¾ÇÕÀûÁ¢±Ù
  • comprehensive field irradiation
    ±¤¹üÀ§Á¶»ç
  • comprehensive health care
    Æ÷°ýº¸°ÇÀÇ·á
  • compress
    1. ÂòÁú 2. ÂòÁúÆÐµå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • completion rate
    ¿Ï¼º·ü
  • complex
    º¹ÇÕ, º¹ÇÕü, ÄÞÇ÷º½º
  • complex cell
    º¹ÇÕ¼¼Æ÷
  • complex compound
    º¹ÇÕÈ­ÇÕ¹°
  • complex echo pattern
    º¹Àâ¸Þ¾Æ¸®, º¹ÇÕ¿¡ÄÚ¾ç»ó
  • complex follicle
    º¹ÇÕÅÐÁý, º¹ÇÕÅÐÁÖ¸Ó´Ï
  • complex molecule
    º¹ÇÕºÐÀÚ
  • complex odontoma
    º¹À⼺ġ¾ÆÁ¾
  • complex partial seizure
    º¹ÇպκйßÀÛ
  • complex position sense
    º¹ÇÕÀ§Ä¡°¨°¢
  • complex potential
    º¹ÇÕÀüÀ§
  • complex receptive field
    º¹ÇÕ¼ö¿ë¾ß
  • complex regional pain syndrome
    º¹ÇÕ±¹¼Òµ¿ÅëÁõÈıº
  • complex repetitive discharge
    º¹ÇÕ¿¬¼Ó¹æÀü
  • complex simple fracture
    º¹Àâ´Ü¼ø°ñÀý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • commotion<³ª> commotio
    ÁøÅÁ(Áõ).
  • communicability
    Àü¿°¼º
  • communicable
    Àü¿°¼ºÀÇ.
  • communicable disease
    Àü¿°º´
  • communicable disease control
    Àü¿°º´°ü¸®(ÊÙË´Ëö), Àü¿°º´¿¹¹æ.
  • communicans
    ±³Åë(Îß÷×).
  • communicated movement
    °øµ¿¿îµ¿(ÍìÔÒê¡ÔÑ)
  • communicating branch
    ±³Åë°¡Áö, ±³ÅëÁö(Îß÷×ò«).
  • communicating branch
    ±³Åë°¡Áö
  • communicating hydrocele
    ±³Å뼺 À½³¶¼öÁ¾
  • communicating hydrocephalus
    ±³Å뼺¼öµÎÁõ(Îß÷×àõâ©Ôéñø)
  • communicating hydrocephalus
    ±³Å뼺 ¼öµÎÁõ(Îß÷×àõ â©Ôéñø)
  • communicating hydrocephaly
    ±³Å뼺 ¼öµÎÁõ(Îß÷×àõâ©Ôéñø).
  • communicating junction
    Àü´Þ°áÇÕ.
  • communicating junction
    Àü´Þ°áÇÕ(îîӹ̿ùê).
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
complement 1s <enzyme> The activated form of complement 1 which has hydrolase activity. In the classical pathway, it splits first c4 and then c2 into active components, thereby generating a new enzyme referred to as eac142 or c42 or c3 convertase.
Registry number: EC 3.4.21.42
(12 Dec 1998)
complement 2 The third component in the complement reaction sequence. It is a beta-globulin with a molecular weight of 117,000, a serum concentration of 30 micrograms/ml and a sedimentation coefficient of 4. It activates c3.
(12 Dec 1998)
complement 3 The fourth component to attach in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 5.5, a molecular weight of 185,000 and a serum concentration of 1.3 micrograms/ml. Its fragments have anaphylatoxic, chemotactic, and histaminic action and affect smooth muscle.
(12 Dec 1998)
complement 3 convertase <enzyme> The enzyme which in both the classical and alternate complement pathways cleaves complement 3 into anaphylatoxin (c3a) and c3b.
Registry number: EC 3.4.21.43
(12 Dec 1998)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement 3a <chemical> Smaller fragment formed when c3 convertase splits c3 into c3a and c3b. C3a is a 77-amino acid peptide that includes a carboxy-terminal arginine which is crucial for its biological activities. C3a causes symptoms of immediate hypersensitivity (anaphylaxis) including smooth muscle contraction, mast cell histamine release, and local inflammation. It is considered an anaphylatoxin along with c4a, c5a, and c5a des-arginine.
Chemical name: Complement C3a
(12 Dec 1998)
complement 3b <chemical> The larger fragment formed when c3 convertase splits c3 into c3a and c3b. In both the classical and alternate pathway, c3b participates in immune adherence and enhances phagocytosis. It also forms a cellular intermediate which continues the complement process. In the alternate pathways, c3b initiates a positive feedback activation of c3pase.
Chemical name: Complement C3b
(12 Dec 1998)
complement 3b inactivators Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop.
(12 Dec 1998)
complement 3c <chemical> An inactivated form of complement 3b (c3b). Complement 3b is inactivated with the help of two regulatory factors, complement factor h and complement factor I. Complement factor h (c3b inactivator accelerator) makes c3b susceptible to the serine protease, complement factor I (formerly called kaf, c3binf, or enzyme 3b inactivator), to form ic3b. Then complement factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg.
Chemical name: Complement C3c
(12 Dec 1998)
complement 3d <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g.
Chemical name: Complement C3d
(12 Dec 1998)
complement 4 The second component to react in the complement sequence. It is a beta-globulin with a sedimentation coefficient of 18.7, a molecular weight of 240,000 and a serum concentration of 430 micrograms/ml. It is activated by complement 1 and serves as a receptor for c2.
(12 Dec 1998)
complement 4a <chemical> Smaller fragment formed when c1s splits c4 into c4a and c4b. As an anaphylatoxin, c4a causes symptoms of immediate hypersensitivity but it has weaker activity than c3a or c5a.
Chemical name: Complement C4a
(12 Dec 1998)
complement 4b <chemical> Larger fragment formed when c1s splits c4 into c4a and c4b. C4b combines with c2b to form the activated c4b2b complex which is often called the classical pathway c3 convertase.
Chemical name: Complement C4b
(12 Dec 1998)
complement 5 The fifth component in the complement reaction sequence, probably exists in a complex with c6 and c7. It is a beta-globulin with a sedimentation coefficient of 10, serum concentration of 75 micrograms/ml and molecular weight of 180,000. It is activated by c423 and releases fragments with anaphylatoxic, chemotactic, and histamine-releasing actions and affecting smooth muscle.
(12 Dec 1998)
complement 5a <chemical> Smaller fragment formed when c5 convertase splits c5 into c5a and c5b. C5a is a 74-amino acid peptide that includes a carboxy-terminal arginine crucial for its spasmogenic activity and a carbohydrate moiety. C5a is the most potent anaphylatoxin mediating immediate hypersensitivity.
Chemical name: Complement C5a
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 20
  • Complement C5a - »õâ The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION.
    Synonyms : C5a Complement, Complement 5a, Complement Component 5a, 5a, Complement Component, C5a, Complement, Complement, C5a, Component 5a, Complement
  • Complement C5a, des-Arginine - »õâ A derivative of complement C5a, generated when the carboxy-terminal ARGININE is removed by CARBOXYPEPTIDASE B present in normal human serum. C5a des-Arg shows complete loss of spasmogenic activity though it retains some chemotactic ability (CHEMOATTRACTANTS).
    Synonyms : C5 a, des-Arg, C5 a, des-Arginine, C5a des-Arg, C5a des-Arginine, C5a, des-Arg, C5a, des-Arginine, Complement 5a, de-Arginine, Complement 5a, des-Arginine, C5 a, des Arg, C5 a, des Arginine, C5a des Arginine, C5a, des Arg, C5a, des Arginine, des-Arg C5 a
  • Complement C5b - »õâ The larger fragment generated from the cleavage of C5 by C5 CONVERTASE that yields COMPLEMENT C5A and C5b (beta chain + alpha' chain, the residual alpha chain, bound by disulfide bond). C5b remains bound to the membrane and initiates the spontaneous assembly of the late complement components to form C5b-8-poly-C9, the MEMBRANE ATTACK COMPLEX.
    Synonyms : C5b Complement, Complement 5b, Complement Component 5b, C5b, Complement, Complement, C5b, Component 5b, Complement
  • Complement C6 - »õâ A 105-kDa serum glycoprotein with significant homology to the other late complement components, C7-C9. It is a polypeptide chain cross-linked by 32 disulfide bonds. C6 is the next complement component to bind to the membrane-bound COMPLEMENT C5B in the assembly of MEMBRANE ATTACK COMPLEX. It is encoded by gene C6.
    Synonyms : C6 Complement, Complement 6, Complement Component 6, C6, Complement, Complement, C6, Component 6, Complement
  • Complement C7 - »õâ A 93-kDa serum glycoprotein encoded by C7 gene. It is a polypeptide chain with 28 disulfide bridges. In the formation of MEMBRANE ATTACK COMPLEX; C7 is the next component to bind the C5b-6 complex forming a trimolecular complex C5b-7 which is lipophilic, resembles an integral membrane protein, and serves as an anchor for the late complement components, C8 and C9.
    Synonyms : C7 Complement, Complement 7, Complement Component 7, C7, Complement, Complement, C7, Component 7, Complement
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
combined androgen blockade treatment of prostate cancer by blocking both testicular and adrenal androgens, usually through orchiectomy followed by administration of an agent that blocks adrenal androgens.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
combined aphasia aphasia of two or more forms occurring concomitantly in the same person.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
combustion equivalent the heat value of a gram of fat or carbohydrate burned outside the body. It measures the amount of potential energy of the substance available, in the form of food, for the production of heat or the supply of energy.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
comfortization (com
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
Commando's operation an operation for management of oral cancer, consisting in resection of the primary lesion and the regional lymphatic nodes.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • comminuted
    ¼¼ºÐÇÑ
  • comminution
    ºÐ¼â;¼¼ºÐ;ºÐ¼â°ñÀý
  • commiserable
    °¡¿²Àº
  • commiserate
    °¡¿²°Ô ¿©±â´Ù
  • commiserate
    °¡¿²°Ô ¿©±â´Ù;µ¿Á¤ÇÏ´Ù;ºÒ½ÖÇÏ°Ô »ý°¢ÇÏ´Ù;ºÒ½ÖÈ÷ ¿©±â´Ù;µ¿Á¤ÇÏ´Ù
  • commiseration
    µ¿Á¤
  • commiseration
    ¿¬¹Î;µ¿Á¤;µ¿Á¤(¾Öµµ)ÀÇ ¸»
  • commiserative
    µ¿Á¤½É ÀÖ´Â;ÀÎÁ¤ ¸¹Àº;~ly
  • commissar
    ÀιÎÀ§¿ø
  • commissar
    (¼Ò·ÃÀÇ)°ø»ê´ç ÅëÁ¦À§¿ø;ÀιÎÀ§¿ø(´Ù¸¥ ³ª¶óÀÇ Àå°ü¿¡ ÇØ´ç)
  • commissarial
    ´ë¸®ÀÚÀÇ;°¨µ¶(ÁÖ±³)´ë¸®ÀÇ;º´ÂüÀå±³ÀÇ
  • commissarial
    º´ÂüºÎ(¿ø);½Ä·® °æ¸®ºÎ(¿ø);½Ä·® º¸±Þ;ÀιÎÀ§¿øÈ¸
  • commissariat
    ÀιÎÀ§¿øÈ¸
  • commissary
    ¸ÅÁ¡
  • commissary
    (±¤»ê.Àç¸ñ ¹úä¼ÒÀÇ)¹°ÀÚ ¹è±Þ¼Ò;ÆÇ¸ÅºÎ;¸ÅÁ¡;(ÃÔ¿µ¼Ò µîÀÇ)±¸³» ½Ä´ç;º´ÂüºÎ(Àå±³);´ë¸®ÀÎ;=COMMISSAR;ÁÖ±³´ë¸®;°æÂû±¹Àå
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 12 ÆäÀÌÁö: 20
COM occur
COM gather or bring together
COM gather together over time
COM start running, functioning, or operating, as of lights or power
COM bring forth, usually something desirable
COM move toward, travel toward something or somebody or approach something or somebody
COM move upward
COM come up, of celestial bodies
COM come to the surface
COM get something or somebody for a specific purpose
COM originate or come into being
COM be mentioned
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 20
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á